Shares of Dr Reddy's Laboratories added 2 percent intraday Wednesday as the company is planning for phase 2 trial of CA-170.
The company's wholly owned subsidiary Aurigene Discovery Technologies is planning to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.
CA-170 is an oral small molecule targeting the immune checkpoints PDL1 and VISTA.
The phase 2 trial is a result of the initial safety data and preliminary evidence of clinical benefit observed in the trial.
At 10:48 hrs Dr Reddyâ€™s Laboratories was quoting at Rs 2,212.40, up Rs 47.60, or 2.20 percent on the BSE.